Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors

被引：1

作者：

Ku, Geoffrey Y. ^{[1
]}

O'Reilly, Eileen M. ^{[1
]}

Saltz, Leonard B. ^{[1
]}

Schrag, Deborah ^{[3
]}

Maki, Robert G. ^{[2
]}

Kelsen, David P. ^{[1
]}

Ilson, David H. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, Dept Med, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Melanoma & Sarcoma Serv, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Ctr Gastrointestinal Oncol, Boston, MA 02115 USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 04期

关键词：

Cisplatin; 5-Fluorouracil; Irinotecan; Phase I trial; METASTATIC COLORECTAL-CANCER; ADVANCED ESOPHAGEAL CANCER; RANDOMIZED-TRIAL; PLUS FLUOROURACIL; ORAL CAPECITABINE; GASTRIC-CANCER; RADIOTHERAPY; LEUCOVORIN; CHEMOTHERAPY; EPIRUBICIN;

D O I：

10.1080/07357900802406327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan. Methods: Twenty-nine patients received cisplatin 25 mg/m2 and bolus 5-FU 425 mg/m2, along with irinotecan at 40, 50, and 65 mg/m2 weekly for 4 out of 6 weeks. Results: The maximum tolerated dose (MTD) for untreated patients was irinotecan 65 mg/m2 while the MTD for previously treated patients was irinotecan 40 mg/m2. Neutropenia and diarrhea were the major dose-limiting toxicities. Antitumor activity was noted in gastric, esophageal and pancreatic cancers. Conclusion: Because of the toxicity profile, combinations with continuous infusion 5-FU or capecitabine should be explored.

引用

页码：402 / 406

页数：5

共 20 条

[1]

[Anonymous], 2005, PRINCIPLES PRACTICE

[2] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[3]

ENZINGER P, 2005, P GASTROINTEST AM SO

[4] Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer [J].

Forastiere, AA ;

Goepfert, H ;

Maor, M ;

Pajak, TF ;

Weber, R ;

Morrison, W ;

Glisson, B ;

Trotti, A ;

Ridge, JA ;

Chao, C ;

Peters, G ;

Lee, DJ ;

Leaf, A ;

Ensley, J ;

Cooper, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2091-2098

[5] COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].

HERSKOVIC, A ;

MARTZ, K ;

ALSARRAF, M ;

LEICHMAN, L ;

BRINDLE, J ;

VAITKEVICIUS, V ;

COOPER, J ;

BYHARDT, R ;

DAVIS, L ;

EMAMI, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598

[6] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

[7]

ILSON D, 2004, P GASTROINTEST AM SO

[8] Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer [J].

Ilson, DH ;

Bains, M ;

Kelsen, DP ;

O'Reilly, E ;

Karpeh, M ;

Coit, D ;

Rusch, V ;

Gonen, M ;

Wilson, K ;

Minsky, BD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2926-2932

[9] Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer [J].

Ilson, DH ;

Saltz, L ;

Enzinger, P ;

Huang, Y ;

Kornblith, A ;

Gollub, M ;

O'Reilly, E ;

Schwartz, G ;

DeGroff, J ;

Gonzalez, G ;

Kelsen, DP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3270-3275

[10]

Kummar S., 2005, CANC PRINCIPLES PRAC, P358

← 1 2 →